The monoclonal antibody format shows superior in vitro activity
Candidate monoclonal antibodies bind human, monkey and rabbit FXI with higher activity than the reference compound, and one candidate selectively inhibits FXIA enzymatic activity significantly better than the reference.
SY2030 shows robust inhibition of thrombus formation in a rabbit AV-SHUNT model
In rabbits, the bispecific SY2030 antibody is non-inferior to the reference compound in inhibiting thrombus formation.
SY2030 carries a lower bleeding risk in the rabbit AV-SHUNT model
The bispecific SY2030 triggers a lower bleeding risk in rabbits than the reference compound, has no significant effect on body weight, and maintains blood flow velocity in a balanced range.
Venous thromboembolism (VTE) is the third most common cause of cardiovascular death worldwide. VTE includes deep vein thrombosis (DVT) and pulmonary embolism (PTE), affecting nearly 10 million people globally each year, more than two-thirds of whom present with DVT. In China, there are approximately 300,000–600,000 new VTE cases annually. Recurrence rates are high, exceeding 25% at five years. Anticoagulation is the mainstay of VTE treatment, yet major bleeding risk may exceed 3% in patients on long-term anticoagulation. The exact pathogenesis of VTE is not fully understood; major triggers include surgery and active malignancy. DVT typically presents as leg pain or swelling, and is sometimes asymptomatic. In DVT patients, a thrombus in the vein may detach, travel with the bloodstream and lodge in the lungs, obstructing blood flow (pulmonary embolism) and ultimately causing death.
Unlike factor Xa, FXI/FXIa act mainly in the intrinsic coagulation pathway. Because FXI and FXIa are more closely linked to thrombus formation than to normal haemostasis, FXI plays a supporting role in haemostasis but a key role in thrombosis. Patients with severe FXI deficiency rarely experience spontaneous bleeding, and their risk of central nervous system or gastrointestinal bleeding is not increased. FXI or FXIa inhibitors may therefore carry a relatively lower risk of major bleeding than current anticoagulants, making them a research focus in anticoagulation therapy. Clinical studies have confirmed FXI as an excellent target for anticoagulant development.
SY2030, developed independently by Symray Biopharma, is a first-in-class biparatopic bispecific antibody against venous thromboembolism, fully covered by our own intellectual property. By simultaneously targeting two functional epitopes of FXI (A2 and catalytic domain), it more effectively inhibits FXI activity and blocks the intrinsic coagulation pathway, providing better protection against thrombus formation and thereby treating VTE. Compared with the most advanced clinical-stage compound in this class, SY2030 shows better FXI binding activity and superior in vitro and in vivo efficacy, making it a preferred option for the treatment of VTE.
1、Venous thromboembolism.Review Lancet.2021 Jul 3;398(10294):64-77.
2. Thrombosis: Targeting factor Xla. Comment Nat Rev Cardiol.2016 Nov;13(11):632
3, An update on factor XI structure and function. Review Thromb Res.2018 Jan;161:94- 105.
4.Abelacimab for Prevention of Venous Thromboembolism. N Eng! J Med 2021;385:609-617.
5. Factor Xla-specificlgG and a reversal agent to probe factor XI functionin thrombosis andhemostasis. Sci Trans Med.2016 Aug 24,8(353)353
6. Contact Activation Inhibitor and Factor X1 Antibody,AB023, roduces Safe, DoseDependent Anticoagulation in a Phase 1 Firstih-Human Trial.